论文部分内容阅读
对化疗耐药性卵巢癌可进行内分泌治疗。Hasan等设计了一个II期临床试验,以评价他莫昔芬(TAM)和格舍瑞林治疗化疗后复发的晚期卵巢癌患者的效果。该方案的作用机理尚未完全清楚。TAM的作用可能和抗雌激素作用有关,特别是对雌激素受体(ER)阳性的肿瘤细胞;临床前试验还表明TAM可抑
Chemotherapy resistant ovarian cancer can be endocrine therapy. Hasan et al. Designed a phase II trial to evaluate the efficacy of tamoxifen (TAM) and goserelin in patients with advanced ovarian cancer who relapsed after chemotherapy. The mechanism of action of this program is not fully understood. The role of TAM may be related to anti-estrogen effects, especially on estrogen receptor (ER) -positive tumor cells; preclinical testing also indicates that TAM is suppressive